Oura prepares for an IPO with a $60.8 million profit, balancing retail partnerships with Amazon and Best Buy against regulatory scrutiny and legal challenges over its sleep-tracking claims.
Wearable ring maker Oura has filed for an initial public offering, reporting a significant jump in net income to $60.8 million for the nine months ending June 30. The company, which maintains partnerships with medtech firms like Dexcom and Resmed, is navigating a transition toward FDA-regulated medical device features while facing a class-action lawsuit regarding the accuracy of its sleep tracking technology.
Oura is transitioning from wellness-exempt features to potentially regulated medical device status, requiring FDA authorization for new health-tracking capabilities.
Revenue is driven by hardware sales through retailers like Amazon, Best Buy, and Target, complemented by a subscription model that boasts a 94% conversion rate.